In a large-scale nuclear emergency, hundreds of thousands of people need assessments to determine levels of radiation absorption. People with toxic exposure can go days without presenting symptoms.
MRIGlobal, Thermo Fisher Scientific, and Arizona State University (ASU) will clinically test and validate for FDA clearance the ARad Biodosimetry Test. Developed by ASU, the ARad Biodosimetry test determines absorbed doses of ionizing radiation in near real-time and informs the use of medical countermeasures following a radiation or nuclear incident.
Until now, there was no way to determine the extent of radiation absorbed into the organs. Using the ARad Biodosimetry test, blood samples can be analyzed for up to seven days post-exposure to measure how genes respond to different amounts of radiation.
The test generates results in approximately 8 hours, providing rapid response capabilities (and throughput sample analysis) with a potential to process more than 400,000 samples a week.